TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Rhea-AI Summary
Immutep (NASDAQ: IMMP) announced on March 13, 2026 that an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study in first-line non-small cell lung cancer after a planned interim futility analysis.
Enrollment will be halted, the study will be wound down with patient follow-up and site close-out, and Immutep says it is reviewing the data and next steps. The company now expects its cash runway to extend well beyond its prior guidance of Q2 CY2027 and will provide an updated outlook after operational assessments.
Positive
- Cash runway extended beyond Q2 CY2027
- Orderly wind down with patient follow-up and site close-out
Negative
- TACTI-004 discontinued after IDMC futility recommendation (March 13, 2026)
- Enrollment halted for the Phase III first-line NSCLC study
News Market Reaction – IMMP
On the day this news was published, IMMP declined 82.44%, reflecting a significant negative market reaction. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1.91B from the company's valuation, bringing the market cap to $407M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data flag a sector move: 2 peers (e.g., EDIT, CADL) were also moving down (median about -2.4%) with no company-specific headlines, suggesting broader biotech pressure alongside this stock’s catalyst.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 06 | TACTI-004 enrolment | Positive | +0.0% | Reached 50% enrolment in global TACTI-004 Phase III NSCLC trial. |
| Dec 22 | IMP761 Phase I data | Positive | +4.9% | Positive Phase I safety and PK/PD data for IMP761 in autoimmune diseases. |
| Dec 16 | TACTI-004 progress update | Positive | +2.0% | Strong operational progress and robust enrolment pace in TACTI-004 Phase III. |
| Dec 02 | AIPAC-003 Phase II data | Positive | -7.1% | New AIPAC-003 breast cancer data with strong responses and immune activation. |
| Nov 13 | EFTISARC-NEO Phase II data | Positive | +2.8% | Phase II EFTISARC-NEO data met primary endpoint in soft tissue sarcoma. |
Clinical trial updates have usually led to modest positive reactions, but there are instances of both flat and negative responses.
Over recent months Immutep has highlighted multiple clinical trial milestones, including strong operational progress in the TACTI-004 Phase III NSCLC program and positive updates from IMP761, AIPAC-003, and EFTISARC-NEO. Price reactions to these clinical headlines have been mixed, with several positive moves offset by a sharp decline after AIPAC-003 data. Today’s recommendation to discontinue TACTI-004 contrasts with earlier momentum in the same program and follows a period of generally constructive trial updates across the pipeline.
Historical Comparison
In the past year, Immutep released 5 clinical trial updates with an average move of 0.54%, generally showing modest price reactions to clinical data.
Historical clinical headlines tracked steady progress for efti and IMP761 across Phase I–III programs, from enrolment milestones and dose-finding to efficacy signals in multiple indications.
Market Pulse Summary
The stock dropped -82.4% in the session following this news. A negative reaction despite the mention of an extended cash runway beyond Q2 CY2027 fits the pattern of markets penalizing failed late-stage programs. Historically, most clinical trial headlines around efti and IMP761 produced modest moves, with a few sharp declines such as after AIPAC-003 data. The discontinuation of a registrational Phase III study represents a major setback, and sentiment could remain fragile as investors await detailed data and a revised development strategy.
Key Terms
independent data monitoring committee regulatory
futility analysis medical
non-small cell lung cancer medical
cash runway financial
AI-generated analysis. Not financial advice.
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis
SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (“efti”) in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol.
Based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility.
In response to the IDMC’s recommendation, enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations.
“We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial” said Marc Voigt, Chief Executive Officer. “We would like to thank the patients, investigators, and clinical teams who contributed to this important study. We are currently conducting a comprehensive review of the available data to better understand the results and determine the appropriate next steps for the program.”
Immutep remains focused on advancing its pipeline of innovative therapies including efti. Following the discontinuation of TACTI-004, Immutep now anticipates its cash runway will be extended well beyond the previously guided timeframe of Q2 CY2027, which was set prior to the trial's cessation. The Company will provide an updated outlook on its revised cash runway and will reassess capital allocation priorities once operational assessments and a full analysis of the study data have been finalised.
About TACTI-004
TACTI-004 (Two ACTive Immunotherapies) is a randomised, double-blind, controlled Phase III study evaluating eftilagimod alfa (efti), a first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer with no EGFR, ALK or ROS1 genomic tumour aberrations. The global trial was to enrol approximately 756 patients regardless of PD-L1 expression and with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries. Patients were being randomised 1:1 to receive either efti in combination with pembrolizumab and chemotherapy in the treatment arm or pembrolizumab in combination with chemotherapy and placebo in the control arm. The study’s dual primary endpoints were progression-free survival and overall survival.
About Eftilagimod Alfa (Efti)
Efti is a novel immunotherapy that directly activates antigen-presenting cells or APCs (e.g. dendritic cells, monocytes) via the MHC Class II pathway to fight cancer. As an MHC Class II agonist, its activation of APCs engages the adaptive and innate immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important co-stimulatory signals & cytokines that further boost the immune system’s ability to combat cancer.
Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), as well as head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable safety profile has enabled various combinations like with anti-PD-[L]1 immunotherapy, radiotherapy, and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximize value for shareholders. For more information, please visit www.immutep.com.
Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
FAQ
Why did Immutep (IMMP) discontinue the TACTI-004 Phase III study on March 13, 2026?
What immediate actions will Immutep (IMMP) take after halting enrollment in TACTI-004?
How does the TACTI-004 discontinuation affect Immutep's cash runway and guidance for IMMP?
Will Immutep (IMMP) continue developing eftilagimod alfa after the TACTI-004 result?
What does the IDMC futility recommendation mean for patient safety in the TACTI-004 trial?
